Cellectis

AGM Information • Feb 17, 2015

PRESS RELEASE

Cellectis SA Shareholders General Meeting of February 16, 2015

February 17, 2015 – Paris (France) – Cellectis SA Shareholders' General Meeting (Alternext: ALCLS.PA) had been held on Monday, February 16, 2015 in Paris, at its head office.

At the end of the meeting, during which more than 65% of voting rights were exercised, 20 of the 21 resolutions had been adopted.

20 resolutions received more than 96,9% votes in favor. Resolution No. 21, regarding a capital increase reserved for members of a company savings plan, was rejected.

In particular, Cellectis' shareholders voted on:

• Authorization of a share repurchase plan and authorization given to the Board of Directors to retire the shares acquired through it;
• Delegations of authority given to the Board of Directors to increase share capital, in particular in the context of an IPO in the United States.
• Resolutions enable Cellectis to grant its executive officers and employees attractive incentive plans.

The full results of the vote can be examined on the company's website (www.cellectis.com).

For further information, please contact:

Cellectis

Jennifer Moore Phone: +33 (0)1 81 69 16 00 e-mail: media@cellectis.com

BMC Communications - New York City

Brad Miles Phone: 646-513-3125 e-mail: bmiles@bmccommunications.com

About Cellectis

Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered Tcells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN™ products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the NYSE Alternext market (ticker: ALCLS).

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains

forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.